183,917 Shares in Solventum Co. (NYSE:SOLV) Purchased by HBK Investments L P

HBK Investments L P purchased a new position in Solventum Co. (NYSE:SOLV) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 183,917 shares of the company’s stock, valued at approximately $12,823,000. HBK Investments L P owned approximately 0.11% of Solventum at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Trian Fund Management L.P. lifted its stake in Solventum by 32.9% in the third quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares during the last quarter. Davis Selected Advisers bought a new position in shares of Solventum in the second quarter valued at approximately $273,070,000. Nuance Investments LLC bought a new stake in shares of Solventum during the 2nd quarter worth $115,829,000. Newport Trust Company LLC bought a new position in Solventum in the 2nd quarter worth $98,976,000. Finally, Baupost Group LLC MA acquired a new stake in shares of Solventum in the second quarter valued at about $96,242,000.

Solventum Stock Performance

Shares of SOLV stock opened at $72.48 on Friday. The stock’s fifty day simple moving average is $70.52 and its 200 day simple moving average is $62.54. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SOLV shares. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Piper Sandler boosted their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. BTIG Research began coverage on Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. Wells Fargo & Company lowered their price objective on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Finally, Wolfe Research started coverage on Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.